文献速递前列腺癌

镭-223治疗去势抵抗性前列腺癌骨转移的三年安全性:ALSYMPCA三期试验更新

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
PubMed 文献 · Eur Urol · 2017-07-11

ALSYMPCA三期随机试验安全性分析纳入600例接受镭-223和301例接受安慰剂的患者,长期随访至首次注射后3年。镭-223组与安慰剂组3/4级贫血均为13%,中性粒细胞减少2% vs 1%,血小板减少7% vs 2%。长期随访未观察到急性髓系白血病、骨髓增生异常综合征或新发原发性骨癌,镭-223仍耐受良好。

要点

  • 镭-223组与安慰剂组3/4级贫血发生率均为13%,骨髓抑制发生率低
  • 长期随访未观察到急性髓系白血病、骨髓增生异常综合征或新发原发性骨癌
  • 1例镭-223患者末次注射后16个月发生再生障碍性贫血,未观察到其他病例

核心结论

  • 最终长期安全性分析显示镭-223仍耐受良好,骨髓抑制发生率低,无新的安全性问题。

研究设计与样本

  • ALSYMPCA为三期随机试验,安全性分析纳入至少接受1次研究药物注射的患者600例(镭-223)和301例(安慰剂)。
  • 405例镭-223和167例安慰剂患者进入长期安全性随访,从末次注射后12周开始至首次注射后3年。
  • 405例镭-223患者中48例(12%)和167例安慰剂患者中12例(7%)完成随访,前6个月每2个月评估一次,之后每4个月评估一次直至3年。

主要发现

  • 治疗至末次注射后12周期间,镭-223组564/600例(94%)和安慰剂组292/301例(97%)发生治疗期间不良事件(TEAE)。
  • 镭-223组与安慰剂组3/4级血液学TEAE:贫血13% vs 13%,中性粒细胞减少2% vs 1%,血小板减少7% vs 2%。
  • 镭-223组98/600例(16%)和安慰剂组68/301例(23%)发生5级TEAE。
  • 长期随访未观察到急性髓系白血病、骨髓增生异常综合征或新发原发性骨癌;非治疗相关继发恶性肿瘤在镭-223组4例、安慰剂组3例。
  • 1例镭-223患者末次注射后16个月发生再生障碍性贫血,未观察到其他病例。

局限性

  • 局限性包括随访时间短(3年)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment. OBJECTIVE: To report updated ALSYMPCA safety, including long-term safety up to 3 yr after the first injection. DESIGN, SETTING, AND PARTICIPANTS: Safety analyses from phase 3 randomized ALSYMPCA trial included patients receiving ≥1 study-drug injection (600 radium-223 and 301 placebo). Patients (405 radium-223 and 167 placebo) entered long-term safety follow-up starting 12 wk after the last study-drug injection, to 3 yr from the first injection. Forty-eight of 405 (12%) radium-223 and 12/167 (7%) placebo patients completed follow-up, with evaluations every 2 mo for 6 mo, then every 4 mo until 3 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: All adverse events (AEs) were collected until 12 wk after the last injection; subsequently, only treatment-related AEs were collected. Additional long-term safety was assessed by development of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), aplastic anemia, and secondary malignancies. Data analysis used descriptive statistics. RESULTS AND LIMITATIONS: During treatment to 12 wk following the last injection, 564/600 (94%) radium-223 and 292/301 (97%) placebo patients had treatment-emergent AEs (TEAEs). Myelosuppression incidence was low. Grade 3/4 hematologic TEAEs in radium-223 and placebo groups were anemia (13% vs 13%), neutropenia (2% vs 1%), and thrombocytopenia (7% vs 2%). Ninety-eight of 600 (16%) radium-223 and 68/301 (23%) placebo patients experienced grade 5 TEAEs. Long-term follow-up showed no AML, MDS, or new primary bone cancer; secondary non-treatment-related malignancies occurred in four radium-223 and three placebo patients. One radium-223 patient had aplastic anemia 16 mo after the last injection. No other cases were observed. Limitations include short (3-yr) follow-up. CONCLUSIONS: Final long-term safety ALSYMPCA analysis shows that radium-223 remained well tolerated, with low myelosuppression incidence and no new safety concerns. PATIENT SUMMARY: Updated Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial findings show that radium-223 remained well tolerated during treatment and up to 3 yr after each patient's first injection.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Parker CC, Coleman RE, Sartor O, et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2017. PMID: 28705540. doi:10.1016/j.eururo.2017.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。